Search results
Results From The WOW.Com Content Network
Cryoprecipitate, also called cryo for short, or Cryoprecipitate Antihemophilic factor (AHF), is a frozen blood product prepared from blood plasma. [1] To create cryoprecipitate, Plasma is slowly thawed to 1–6 °C. A cold-insoluble precipitate is formed, which is collected by centrifugation, resuspended in a small amount of residual plasma ...
The term cryosupernatant (also called cryo-poor plasma, cryoprecipitate depleted, cryoprecipitate reduced plasma) refers to plasma from which the cryoprecipitate has been removed. It is used to treat thrombocytopenic purpura .
Much of the donor blood supply is obtained at "remote" blood donation events, such as blood drives at colleges, community events, etc., rather than at dedicated donation centers. The time required for transportation and processing often precludes production of FFP in such cases; that is the plasma cannot be separated and frozen within 8 hours ...
Fresh frozen plasma (FFP) is a blood product made from the liquid portion of whole blood. [3] It is used to treat conditions in which there are low blood clotting factors (INR > 1.5) or low levels of other blood proteins. [3] [1] It may also be used as the replacement fluid in plasma exchange.
Routine use of fresh frozen plasma (FFP) is not generally appropriate because of the dangers including citrate toxicity (from the anticoagulant), ABO incompatibility, infection, and allergic reactions. However, FFP should be used in cases of thrombotic thrombocytopenic purpura or patients at high risk of bleeding.
Packed red blood cells, fresh frozen plasma, and platelets are generally administered. [131] Typical ratios of fresh frozen plasma, platelets and packed red blood cells are between 1:1:1 and 1:1:2. [132] In some locations, blood has begun to be administered pre-hospital in an effort to reduce preventable deaths from significant blood loss.
Prothrombin complex concentrate, cryoprecipitate and fresh frozen plasma are commonly used coagulation factor products. Recombinant activated human factor VII is sometimes used in the treatment of major bleeding. Tranexamic acid and aminocaproic acid inhibit fibrinolysis and lead to a de facto reduced bleeding rate.
People with AHTR are managed with supportive care, which may include diuretics, blood pressure support, and treatment of disseminated intravascular coagulation (with fresh frozen plasma, cryoprecipitate, and platelet transfusion). [6] The use of steroids, intravenous immune-globulins or plasma exchange is not supported by evidence. [6]